Infliximab biosimilar-to-biosimilar switching in patients with inflammatory rheumatic disease: clinical outcomes in real-world patients from the DANBIO registry

Hafsah Nabi*, Oliver Hendricks, Dorte Vendelbo Jensen, Anne Gitte Loft, Jens Kristian Pedersen, Søren Andreas Just, Kamilla Danebod, Heidi Lausten Munk, Salome Kristensen, Natalia Manilo, Ada Colic, Asta Linauskas, Pia Høger Thygesen, Louise Brot Christensen, Maren Høgberget Kalisz, Niels Lomborg, Stavros Chrysidis, Johnny Lillelund Raun, Marlene Andersen, Frank MehnertNiels Steen Krogh, Merete Lund Hetland, Bente Glintborg

*Corresponding author af dette arbejde

Abstrakt

OBJECTIVE: Successful uptake of biosimilars in rheumatology is limited by lack of real-world evidence regarding effectiveness of biosimilar-to-biosimilar switching. We investigated infliximab biosimilars CT-P13-to-GP1111 switching among patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritis (AxSpA).

METHODS: Observational cohort study from the DANBIO registry. Patients were classified as originator-naïve or originator-experienced. Retention rates of 1-year GP1111 treatment were explored (Kaplan-Meier). We identified baseline factors (at the time of switch) associated with withdrawal of GP1111 (multivariable Cox-regression analyses with HRs including originator treatment history). Changes in subjective and objective measures of disease activity 4 months before and after the switch were assessed in individual patients.

RESULTS: Of 1605 patients (685 RA, 314 PsA and 606 AxSpA, median disease duration was 9 years, 37% in Clinical Disease Activity Index/Ankylosing Spondylitis Disease Activity Score remission), 1171 were originator-naïve. Retention rates at 1-year were 83% (95% CI: 81% to 85%) and 92% (95% CI: 90% to 95%) for the originator-naïve and originator-experienced, respectively. GP1111 retention rates were higher in originator-experienced compared to originator-naïve with RA (HR=0.4 (95% CI: 0.2 to 0.7)) and PsA (HR=0.2 (95% CI: 0.1 to 0.8)), but not significantly for AxSpA: HR=0.6 (95% CI: 0.3 to 1.2). Lower disease activity was associated with higher retention. Changes in disease activity preswitch and postswitch were close to zero.

CONCLUSION: This real-world observational study of more than 1600 patients with inflammatory arthritis showed high 1-year retention following a nationwide infliximab biosimilar-to-biosimilar switch. Retention was higher in originator-experienced and in patients with low disease activity, suggesting outcomes to be affected by patient-related rather than drug-related factors.

OriginalsprogEngelsk
Artikelnummer002560
TidsskriftRMD Open
Vol/bind8
Udgave nummer2
ISSN2056-5933
DOI
StatusUdgivet - nov. 2022

Fingeraftryk

Dyk ned i forskningsemnerne om 'Infliximab biosimilar-to-biosimilar switching in patients with inflammatory rheumatic disease: clinical outcomes in real-world patients from the DANBIO registry'. Sammen danner de et unikt fingeraftryk.

Citationsformater